Dr. John Glees of Cancer Centre London Pioneering Treatment for Dupuytren's with Xstrahl Orthovoltage Systems
Dupuytren’s contracture (trigger finger) is a painful disease experienced by many. Cancer Centre London Parkside is pioneering a non-invasive radiotherapy treatment for Dupuytren’s using Xstrahl’s X-Ray therapy systems.
Dr. John Glees, a world-renowned specialist in low dose radiotherapy for benign disease, says “with this non-invasive treatment, nearly 9 out of 10 people see the progression of the disease being stopped or even reversed with no significant side effects.”
Xstrahl’s superficial and orthovoltage X-Ray therapy systems are currently being used around the world by medical specialists to treat benign diseases such as Dupuytren’s contracture, keloids, plantar fasciitis and psoriasis. Radiotherapy is a non-surgical treatment option which is ideal for many benign diseases.
Xstrahl Releases German Language Micro-Site
Xstrahl is pleased to announce the release of a German micro-site on Xstrahl.com. Access to this German language addition to our website is through a Deutschland flag set into the navigation bar.
This new language site is just another way that Xstrahl is servicing its customers in Germany and Austria. This is in addition to the recent hiring of two new Europe-based representatives, Bea Mattheis-Koschel and Casper Dercksen.
Xstrahl is a leading designer and manufacturer of superficial and orthovoltage X-Ray therapy systems used in the treatment of superficial skin conditions (including some cancers), as well as for the palliation of superficial cancers not suited to surgical treatment. Xstrahl is also the home of the superficial therapy educational programme (STEP), which provides information on the use of low energy X-Rays and treatment of both benign and malignant skin conditions.
Xstrahl to Attend DEGRO 2012 in Wiesbaden June 7 to 10th
Xstrahl will attend this year's Deutschen Gesellschaft für Radioonkologie e.V. (DEGRO) in Wiesbaden, Germany.
Visit Xstrahl in booth 902, where the Xstrahl team will be available for demonstrations of our clinical X-Ray therapy systems.
Xstrahl offers both superficial and orthovoltage X-Ray therapy systems which are used in the treatment of superficial skin cancers. These systems include the Xstrahl 100 and Xstrahl 150 superficial therapy systems, as well as the Xstrahl 200 and 300 orthovoltage systems.
Gulmay Medical (Xstrahl) adds to SARRP Team in U.S.
As a result of recent sales success in the United States, Gulmay Medical has now added two new technical staff to its expanding team of technical research specialists.
Shonna Glen joins Gulmay as an Applications Specialist. She brings with her a wealth of knowledge and experience in biology and dosimetry, having trained physicians and physicists in treatment planning systems. Shonna will use her expertise to train research oncology specialists to use the SARRP (small animal radiation platform) system.
A second addition to the expanding U.S. based SARRP team is Thilakshan Kanesalingam, Gulmay’s new Development Engineer (SARRP). Thilakshan’s strong experience in medical imaging, medial robotics and radiation physics will assuredly complement the needs of the growing SARRP technical team.
We look forward to working with both Shonna and Thilakshan and know that both new additions will play an integral part in the SARRP team’s continued success in the United States.
Visit Xstrahl at ESTRO 31 in Barcelona
Xstrahl will attend this year's European Society for Radiotherapy and Oncology (ESTRO) conference May 9—13th in Barcelona.
Visit Xstrahl in the middle of the Exhibition Hall (booth 3700) and ask for a demonstration of our Xstrahl 100 Mobile X-Ray Therapy system. The Xstrahl team will be available to answer all your radiotherapy questions.
Xstrahl Announces New European Team Expansion
As a result of recent business success and subsequent ongoing expansion, we would like to announce that Beatrice Mattheis-Koschel and Casper Dercksen have now joined the Xstrahl team based in Europe.
Casper, who joins us from Nucletron Benelux in the Netherlands, will be our new International Sales Development Manager and will focus on developing our research sales internationally; he will also lend his expertise in radiotherapy to our medical sales department.
Beatrice joins us from Theranostic GmbH and will be Xstrahl’s Territory Manager (Radiotherapy), DACH Territory, managing sales and service requests for our German and Austrian customers. Beatrice will also be assisting Casper with research sales and inquiries from both Germany and Austria.
We look forward to working with both Beatrice and Casper and know they will both contribute greatly to our future continued success.
Xstrahl to Attend AACR Meeting in Chicago March 31st to April 4th
Xstrahl is attending the American Association of Cancer Research in Chicago March 31st to April 4th.
Visit Xstrahl at the Do You Use Radiation? booth (#1503) where Xstrahl is showcasing their range of radiation based scientific research solutions—find out how cancer research is being enhanced by Xstrahl's SARRP Image Guided Micro-Irradiator (IGMI™); see Xstrahl's range of X-Ray irradiators used in in vivo and in vitro irradiation studies, as well as their X-Ray imaging machines.
Xstrahl Enters into Framework Agreement with NHS Supply Chain to Supply Imaging, Radiotherapy and Ancillary Devices to Hospitals and Medical Radiotherapy Centres in the UK
Xstrahl has entered into a framework agreement with NHS Supply Chain to supply its industry leading superficial and orthovoltage X-Ray Therapy Systems to radiotherapy centres within the United Kingdom.
NHS Supply Chain was established to reduce both the costs and supply chain process time required to acquire medical equipment and supplies for Hospitals and Medical Centres within the UK.
Xstrahl's range of kilovoltage X-Ray Therapy Systems are used in the clinical treatment of superficial skin conditions and some cancers and boney metastases. Xstrahl's medical systems include the Xstrahl 100 and 150, used to treat conditions such as basal cell carcinoma, squamous cell carcinoma, keloid scarring and mycosis fungoides; and the Xstrahl 200 and 300 are used to treat inflammatory, degenerative and hypertrophic disorders, as well as skin conditions and some boney metastases.
Huntington Memorial Hospital Acquires the Xstrahl 100 for the Treatment of Superficial Cancers of the Skin
Ruth Williamson, MD, Medical Director of Huntington Hospital's Breast Cancer Program, says of the hospital's newly acquired Xstrahl 100; "Our new superficial therapy unit is the optimal device for curative radiation treatment of skin cancers. The device delivers a high dose to the skin, yet spares the underlying tissue from radiation. Radiation therapy is an excellent option for small skin cancers when surgery requires reconstruction which, otherwise, could give an unsatisfactory cosmetic result."
This low-energy treatment option delivers outstanding clinical accuracy with excellent cosmetic results, and in many cases, provides a nonsurgical alternative for treating primary skin lesions in the sensitive areas of the head and neck.
Huntington Memorial Hospital is located in Pasadena, California and specializes in cancers of the skin as well as breast cancer.
The 14th International Congress of Radiation Research (ICRR) Commemorates the 100th Year Anniversary of Maria Sklodowksa-Curie's Two Nobel Prizes
Xstrahl attended the 14th International Congress of Radiation Research in Warsaw, Poland, August 28th—September 1st, 2011. The traditional polish-themed conference held at the historic Palace of Culture and Science was hosted by the president of the Congress, Antonina Cebulska-Wasilewska, and marked the 100th year anniversary of Maria Sklodowska-Curie being the first person, and only woman, to win two Nobel prizes.
The conference was well attended by an international audience and featured numerous simultaneous lectures focusing on various aspects of radiation research, including normal tissue effects of radiation, DNA damage response, advances in combined therapies and cancer treatment, environmental radiobiology, hypoxia, radioresistance, dosimetry and ethics.
A debate between Soren Bentzen and Boguslaw Jacek Maciewjewski was held on the topic, "This house believes that further advances in radiation oncology will come from physics rather than from radiation biology," and resulted in an amusing and challenging dicussion.
Awards were presented to the following: Richard Hill, IARR Kaplan Award, David Hirst, ARR Weiss Award, Penny Jeggo, ERRS Bacq Award and Alexander and Dudley Goodhead, the ICRU Gray Medal Award.
Xstrahl exhibted its Small Animal Research Radiation Platform (SARRP) for the first time to a European audience at the conference and was delighted with the interest shown in the platform. A diverse range of questions with regard to current and future applications were answered by the Xstrahl attendees.
Xstrahl would like to thank the organisers and attendees for their interest and looks forward to meeting collaborators and scientists at the next ICTR-PHE conference on February 27th—March 2nd, 2012 in Geneva.
Xstrahl Attends GBS Jahrestagung 2011 in Köln
Xstrahl attended the 14th Annual GBS Jahrestagung meeting of the Society for Biological Radiation Research in Köln, from the 13th—16th of September 2011. This year's annual meeting focused on radiation research and its implications for both people and space. It was held at the University of Bonn-Rhein-Sieg in collaboration with the German Aerospace Center (DLR) and was hosted by Dr. George Iliakis of the University of Duisburg-Essen.
The meeting featured lectures on the mechanics of DNA damage and repair, signal transduction, bystander mechanisms, genomic instability, individual radiation sensitivity, side effects of ionizing radiation, high LET radiation, space radiation therapy aspects and UV radiation as well as current radiation protection issues.
A SpaceLife career day was also organised by the Helmholtz space life sciences research school for September 17th to enable students a chance to liaise with experienced industry scientists and organisations.
Xstrahl's Pioneering SARRP® (Small Animal Radiation Research Platform) Secures First Ever European Commissions
Following a highly successful United States launch of its SARRP, a pre-clinical cancer research platform using image guided micro-irradiation (IGMI™) techniques, which has seen installations at Harvard University, the University of Pennsylvania and the University of Virginia, Xstrahl has now been commissioned with the first ever European SARRP system for the Centre for Advanced Biomedical Imaging at University College London.
This installation will quickly be followed by the delivery of two further European systems for the Department of Molecular Studies, Oxford University and the Institute of Cancer Sciences, University of Glasgow.
Expanding SARRP's continuing success in the United States, the Beaumont Institute in Michigan will take delivery of a SARRP platform, as well as an Xstrahl Radiation Research Cabinet enabled with precise oxygen for hypoxia experiments.
Installation of First European SARRP® (Small Animal Radiation Research Platform) Showcased as Centrepiece at Glittering Reception at University College Hospital London's New Centre for Advanced Biomedical Imaging (CABI)
Xstrahl was a proud sponsor of an inaugural reception April 13, 2011 which took place in London at University College's Paul O'Gorman Building to launch the opening of the new Centre for Advanced Biomedical Imaging (CABI). The centre is the new multidisciplinary research centre for experimental biomedical imaging.
A centrepiece of the instution's research department is Xstrahl's SARRP, a pre-clinical cancer research platform using image guided micro-irradiation (IGMI™) techniques.
Dr. Susan Short, Consultant and Senior Lecturer in Clinical Oncology specialising in translational research at the University College London's Cancer Institute which focuses on molecular aspects of radiobiology and DNA repair in glioma and CNS model systems introduced the new SARRP system to a select audience of over 200 invitees.
The reception was a great success and helped to introduce Xstrahl's cutting-edge SARRP technology, enabling the highly accurate targeting of radiation to brain tumours in the animal model.
Xstrahl is a leading designer and manufacturer of superficial orthovoltage medical X-Ray systems used in the treatment of cancers and dermatological disorders, as well as a pioneer in the development of advanced X-Ray systems for pre-clinical radiation biology research (Life Sciences).
Xstrahl's headquarters are located in Surrey, England and its subsidiary, Gulmay Medical Inc. is in Suwanee, Georgia (United States).
For further information contact:
Adrian Treverton, Sales Director, Gulmay Medical Inc.
Tel: (678) 482-6800
Time zone: (EST) Eastern Standard
Martin Robinson, Chief Executive, Xstrahl Ltd.
Tel: +44 (0) 1276 462 696
Time zone: (CET) Central European
All products have CE, FDA and Health Canada clearance and are certified to ISO13485:2003.